Delivery strategies of RNA therapeutics to leukocytes

Dana Tarab-Ravski, Lior Stotsky-Oterin, Dan Peer

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Harnessing RNA-based therapeutics for cancer, inflammation, and viral diseases is hindered by poor delivery of therapeutic RNA molecules. Targeting leukocytes to treat these conditions holds great promise, as they are key participants in their initiation, drug response, and treatment. The various extra- and intra-cellular obstacles that impediment the clinical implementation of therapeutic RNA can be overcome by utilizing drug delivery systems. However, delivery of therapeutic RNA to leukocytes poses an even greater challenge as these cells are difficult to reach and transfect upon systemic administration. This review briefly describes the existing successful delivery strategies that efficiently target leukocytes in vivo and discuss their potential clinical applicability.

Original languageEnglish (US)
Pages (from-to)362-371
Number of pages10
JournalJournal of Controlled Release
StatePublished - Feb 2022


  • Drug delivery
  • Leukocytes
  • Nanocarriers
  • RNA
  • mRNA

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Delivery strategies of RNA therapeutics to leukocytes'. Together they form a unique fingerprint.

Cite this